Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24 Week, Randomised, Assessor Blinded, Active-controlled, Parallel Group, Phase 3, 2 Arm Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

NCT05259722 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT05259722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05259722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24 Week, Randomised, Assessor Blinded, Active-controlled, Parallel Group, Phase 3, 2 Arm Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
Lead sponsor
LEO Pharma
Phase
Phase 3
Overall status
Completed
Start date
June 15, 2022
Completion date
December 5, 2023
Enrollment
513 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hand eczema